Related Experiment Video
Updated: Mar 6, 2026

Measuring Carbon-based Contaminant Mineralization Using Combined CO2 Flux and Radiocarbon Analyses
Published on: October 21, 2016
Basis for the ICRP's updated biokinetic model for carbon inhaled as CO2
1Environmental Sciences Division, Building 1509, Room 205, Oak Ridge National Laboratory, Oak Ridge, TN 37831, United States of America.
Abstract:
The International Commission on Radiological Protection (ICRP) is updating its biokinetic and dosimetric models for occupational intake of radionuclides (OIR) in a series of reports called the OIR series. This paper describes the basis for the ICRP's updated biokinetic model for inhalation of radiocarbon as carbon dioxide (CO2) gas. The updated model is based on biokinetic data for carbon isotopes inhaled as carbon dioxide or injected or ingested as bicarbonate [Formula: see text] The data from these studies are expected to apply equally to internally deposited (or internally produced) carbon dioxide and bicarbonate based on comparison of excretion rates for the two administered forms and the fact that carbon dioxide and bicarbonate are largely carried in a common form (CO2-H[Formula: see text] in blood. Compared with dose estimates based on current ICRP biokinetic models for inhaled carbon dioxide or ingested carbon, the updated model will result in a somewhat higher dose estimate for 14C inhaled as CO2 and a much lower dose estimate for 14C ingested as bicarbonate.
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Physiological Models
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Carbon Dioxide Transport in the Blood
Forms of CO2 Transport
1. Dissolved in plasma: A small percentage (7-10%) of CO2 is transported and dissolved directly in the plasma.
2. Carbaminohemoglobin: Just over 20% of CO2 is chemically bound to...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

